Encouraging results from earlier pilot studies suggest that vaccinating stem cell donors with Triplex may convey protective CMV-specific T cell immunity to transplant recipients, potentially ...

Fortress Biotech and its subsidiary Helocyte have announced the dosing of the first subject in a multi-centre Phase II trial ...

A still unsolved question is the capability of CMV to induce rejection in solid organ transplant recipients. The absence of compatibility of the system human leukocyte antigen 1 (HLA-1 ...

The CMV genome is composed of lineal ... These mechanisms prompt to a latent infection that may be reactivated in transplant recipients. The purpose of this review is to conduct a critical ...

Cytomegalovirus (CMV) infection is a significant concern for solid organ transplant recipients due to its potential to cause severe complications and impact transplant outcomes. Managing CMV ...

A new study from the Hong Kong Children's Hospital reveals critical insights into the infection risks associated with ...

Credit: Green Apple/Shutterstock. Fortress Biotech and its subsidiary Helocyte have announced the dosing of the first subject in a multi-centre Phase II trial of the cytomegalovirus (CMV) vaccine, ...

Triplex is expected to trigger a CMV-specific immune response in the donor, which is then transferred to the transplant recipient. The initial Phase II trial builds on the findings from the Phase ...

A new study from the Hong Kong Children's Hospital reveals critical insights into the infection risks associated with pediatric allogeneic ...

Introduction An organ transplant is a surgical procedure replacing a damaged organ with a healthy one. Diagnostics for organ transplants are cl ...